

**MARCH 2008 PBAC OUTCOMES - Deferrals**

DRUG AND FORM	DRUG USE AND TYPE	LISTING REQUESTED BY SPONSOR	PBAC OUTCOME AND COMMENT
<p>ALENDRONATE SODIUM with COLECALCIFEROL, tablet, equivalent to 70 mg alendronic acid with 140 micrograms colecalciferol, Fosamax Plus<sup>®</sup> 70/140 Merck Sharp and Dohme (Australia) Pty Ltd</p> <p>Minor submission</p>	<p>Osteoporosis</p>	<p>Authority required (<i>streamlined</i>) listing similar to Fosamax Plus<sup>®</sup> (alendronic acid 70 mg with colecalciferol 70 micrograms).</p>	<p>The PBAC deferred a final decision pending registration of the product by the Therapeutic Goods Administration.</p>
		<p>Sponsor's comments</p>	<p>The sponsor had no comment.</p>
<p>MELOXICAM, tablets, 7.5 mg and 15 mg and capsules, 7.5 mg and 15 mg, Mobic<sup>®</sup> Boehringer Ingelheim Pty Ltd</p> <p>Minor submission</p>	<p>Anti-inflammatory agent</p>	<p>Restricted benefit listing for symptomatic relief of rheumatoid arthritis.</p>	<p>The PBAC deferred a recommendation on this item, noting that it had never formally assessed meloxicam for this use.</p>
		<p>Sponsor's comments</p>	<p>The sponsor had no comment</p>